Update on new approaches in the management of hepatocellular carcinoma

Giuseppe Cabibbo¹,²
Michela Antonucci³
Chiara Genco¹

¹Sezione di Gastroenterologia, Di.Bi.M.i.S., University of Palermo, Italy; ²Dipartimento di Biopatologia e Metodologie Biomediche, University of Palermo, Italy; ³Department of Oncology, Division of General and Oncological Surgery, University of Palermo, Italy

Abstract: Hepatocellular carcinoma (HCC) is a major health problem. It is currently the third cause of cancer-related death, it is highly prevalent in the Asia–Pacific region and Africa, and is increasing in Western countries. The natural history of HCC is very heterogeneous and prediction of survival in individual patients is not satisfactory because of the wide spectrum of the disease. During the past decade, major advances have been achieved in prevention, through better surveillance of patients at risk, and in therapy through better surgical and ablative therapies and multimodal treatment approaches. Moreover, the increasing knowledge of molecular hepatocarcinogenesis provides the opportunity for targeted therapies. In this setting, the impact of sorafenib on advanced-stage HCC is a landmark finding in the treatment of liver cancer. The role of sorafenib administration as adjuvant therapy after curative treatment is being evaluated in clinical studies. Future research should lead to a molecular classification of the disease and a more personalized treatment approach.

Keywords: hepatocellular carcinoma, sorafenib

Introduction to treatment management of hepatocellular carcinoma – update on use of biologics and emerging treatment options

Hepatocellular carcinoma (HCC) is a major health problem. It is the sixth most common cancer worldwide and the third cause of cancer-related death.¹ In 2002 at least 600,000 new cases were registered and its incidence and prevalence in US and Western Europe have been increasing during the past decade. In 80% of cases HCC affects cirrhotic livers and it is now considered the first complication to occur and the major cause of liver-related death.² Principal risk factors for developing cirrhosis and then HCC are chronic liver diseases and in particular chronic B and C hepatitis/cirrhosis, alcoholic liver disease and nonalcoholic steatohepatitis-related cirrhosis.³–⁵ Guidelines for HCC management recommend mortality risk estimates as a decision-making support.⁶ Unfortunately, the ability of all the available prognostic scores to predict mortality is far from perfect and none of these systems provide sufficient confidence for the prediction of the outcome in the individual patient with HCC.³,⁶–⁸

In the absence of an optimum prognostic model, treatment algorithms for patients with HCC in Europe and North America have been prepared on the basis of the Barcelona Clinic Liver Cancer (BCLC) classification.³,⁹,¹⁰

The BCLC staging classification for HCC classifies patients as having stages of disease from 0 to D (Figure 1).
Stage 0 is very early disease, which is defined as a solitary liver cancer that measures ≤2 cm without tumor invasion into surrounding tissues.

Stage A is early disease, classified as patients who exhibit preserved liver function with a solitary HCC ≤5 cm in size, or up to 3 tumors each of which is ≤3 cm in size. Patients with stage 0 or stage A disease can be effectively treated with curative therapies, such as surgical resection, liver transplantation, or by percutaneous ablation methods, including percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA). With these treatments it is possible to obtain complete responses with potential long-term cure, as reflected by a 5-year survival better than 50% to 70%.

The BCLC intermediate stage (stage B) consists of asymptomatic patients with well-preserved liver function, and multinodular or large tumor extension, without macrovascular invasion or extrahepatic spread (ES). Patients with stage B (intermediate) disease treated with transarterial embolization (TAE) or transarterial chemoembolization (TACE) have demonstrated a significant increase in survival compared with best supportive care (median survival, 20 months vs 16 months).

Patients with mild related symptoms and/or macrovascular invasion or ES are classified as advanced stage (BCLC stage C). Previously, no standard systemic therapy existed for the treatment of patients at this stage; however, two randomized controlled trials (RCTs) have now shown that sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor (VEGFR), improves the overall survival of patients with stage C disease. Sorafenib is, therefore, now considered to be the standard treatment for advanced HCC.11,12 Patients with cancer symptoms, related to progressed liver failure, tumor growth with vascular involvement, ES, or physical impairment (performance status ≥2) are classified as stage D (end stage) disease; they do not benefit from antitumor treatments and should receive only the best available supportive care.

It should be noted that not all patients defined by each stage of BCLC are ultimately candidates for the suggested treatment modality.

For instance, TACE can be performed at an early stage in patients for whom RFA or PEI cannot be performed because of tumor location (proximity to a gallbladder, biliary tree, or blood vessel), or because of failed prior curative treatments or medical comorbidities. TACE is also the first-line therapy for downstaging tumors that exceed the criteria for transplantation or in patients awaiting orthotopic liver transplantation (OLT).

Moreover, even if guidelines for the management of HCC provide indications for the use of various treatments as monotherapies, in clinical practice a multimodal approach...
that combines various techniques is used, either as first-line therapy or as a rescue (second-line) approach after the failure of a monotherapy (Table 1).13,14

Review of the natural history and diagnosis of hepatocellular carcinoma

HCC is an insidious disease, with no particular or specific signs and symptoms of manifestation and whose behavior is usually unpredictable. Its natural history is also dependent on functional impairment of the underlying liver disease which often limits the application of therapeutic opportunities and influences survival. The spontaneous course of the unresectable disease has recently been evaluated in a meta-analysis which analyzed the survival rates of the placebo and untreated arms of several RCTs on HCC patients, showing that the 1- and 2-year survival is extremely heterogeneous (Figure 2).15 Moreover, when studies were separated according to the BCLC stage, the 1-year survival was much higher in RCTs including only BCLC B or C patients (34%) than in those also including BCLC D patients (11%).15 For ethical reasons it is not possible to evaluate in RCTs the natural history of early disease or inflammation and cirrhosis in 70% to 90% of all cases. All risk factors for liver cirrhosis play a role in the development of newborn unpaired arteries that present with advanced or unresectable disease. Since the stage of cancer dictates the therapeutic choice, early detection is a primary objective. The goal of cancer screening is to reduce mortality through a reduction in incidence of advanced disease.

Although the optimal methods of screening and the cost-effectiveness of surveillance (the repeated application of screening tests) for HCC remain to be established, systematic screening still offers the best hope for early diagnosis, treatment eligibility, and improved survival.10,18

“Recall policies” are the policies instituted to deal with an abnormal screening test result. Once a hepatic lesion is found during ultrasonographic surveillance, diagnosis of HCC is made through the application of some criteria that have been recently updated by Bruix and Sherman and have been endorsed by the American Association for the study of Liver Diseases.10 According to these criteria, patients with nodules <1 cm in diameter detected by ultrasonography are followed up every 3 to 6 months in order to observe any variation of aspect or dimensions. Nodules >1 cm in diameter should be investigated with at least one dynamic radiological study (4-phase multidetector CT scan or dynamic contrast enhanced MRI). When typical contrast-enhancing behavior of HCC is observed (ie, presence of a hypervascular pattern in arterial phase with a wash out of contrast during the venous and late phase) the lesion should be treated as HCC. If imaging findings are atypical for HCC or uncertain, a second contrast-enhanced study with the other radiological study (4-phase multidetector CT scan or dynamic contrast enhanced MRI). When typical contrast-enhancing behavior of HCC is observed (ie, presence of a hypervascular pattern in arterial phase with a wash out of contrast during the venous and late phase) the lesion should be treated as HCC. If imaging findings are atypical for HCC or uncertain, a second contrast-enhanced study with the other imaging modality should be performed or the lesion should be biopsied (Figure 3).10

Several studies have evaluated the cost-effectiveness of the recall policies.19-21

Overview of the pathophysiological processes associated with hepatocellular carcinoma

Generally, HCC develops on a background of chronic liver disease or inflammation and cirrhosis in 70% to 90% of all cases. All risk factors for liver cirrhosis play a role in the hepatocellular carcinogenesis and liver cirrhosis per se is a precancerous condition.22

HCC is known to show a multistep progression from the hyperplastic nodule to early HCC and finally to moderately/ poorly differentiated HCC (Figure 4). Throughout the course of this pathway, nodules acquire evident changes in vascular supply with development of newborn unpaired arteries that

Table 1 The proposed purpose of combination therapy

| Contextual | • Improved effectiveness over monotherapy for the treatment of single lesions  
| | • Improved effectiveness over monotherapy for the treatment of multiple lesions  
| | • Improved effectiveness over monotherapy for the prevention of tumor recurrence  
| Sequential | • Improved effectiveness over monotherapy for the treatment of large or difficult lesions  
| | • Rescue therapy after the failure of a first-line approach  
| | • Improved effectiveness over monotherapy for the prevention of tumor recurrence after complete response (adjuvant treatment)  
| | • To slow tumor progression for patients awaiting liver transplantation (bridge to transplant)  
| | • To reduce tumor size to meet orthotopic liver transplantation criteria (downstaging)  
| | • To allow for salvage transplantation in patients without proven malignant disease after liver resection if pathological findings (eg, evidence of vascular invasion) indicate the patient is at high risk of tumor recurrence (“salvage” transplantation)  

**Figure 2** Forest plot of 1-year survival rates of the placebo or untreated arms of 30 RCTs using random-effects model. Studies are arranged by publication year. Copyright © 2010, John Wiley and Sons. Adapted with permission from Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology*. 2010;51(4):1274–1283.


**Abbreviations:** MDCT, multidetector computed tomography scan; MRI, magnetic resonance imaging; US, ultrasound.
Figure 4 Schematic representation of multistep progression of human hepatocarcinogenesis. Differentiation between early-stage hepatocellular carcinoma (HCC) and premalignant lesion is extremely important.

Abbreviations: LGDN, low grade dysplastic nodule; HGDN, high grade dysplastic nodule.

progressively replace portal vessels, giving the nodule the typical hypervascular appearance.

The hepatocarcinogenetic process is mostly characterized by the appearance of dysplastic lesions (dysplastic phase) in the form of microscopic foci (large and small cell changes) and macroscopic dysplastic nodules (low and high grade).23,24 This phase is very important because patients harboring these lesions are at increased risk of developing HCC, allowing early tumor detection and consequently improving survival. The possibility of de novo development of HCC without premalignant antecedents is rare, but cannot be excluded.

High-grade dysplastic nodules are the most advanced precursors of HCC and small and well-differentiated HCCs with indistinct margins are the earliest and smallest recognizable forms of HCC (usually <2 cm).

Despite our growing comprehension of the different pathways altered in hepatocellular tumors, the molecular mechanisms that lead to malignant transformation of hepatocytes and give rise to a HCC are still poorly understood. Several epigenetic and genetic alterations are involved in hepatocellular tumorigenesis, leading to mutations in genes that control cell cycle, proliferation, and apoptosis. Different risk factors such as viral infections, oxidative stress, and cirrhotic inflammation induce the initiation of carcinogenesis and then the progressive occurrence of gene mutations contribute to the selection of cells that can proliferate and survive in an uncontrolled way. Principal mutations observed in HCC carcinogenesis are deletions or gains of chromosome segments, point mutations, and epigenetic changes such as hypermethylation of gene promoters.25

During the past few years several possible key molecular pathways involved in HCC’s pathogenesis have been discovered and they represent important potential targets for experimental therapies. The mitogen-activated protein kinase (MAPK) pathway is a cascade of phosphorylation events mediated by four cellular kinases (Ras, Raf, MAP and extracellular signal related kinase [ERK]) that influence cellular proliferation, differentiation, and apoptosis and are frequently involved in HCC pathogenesis. The phosphoinositide-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway includes a group of cellular kinases that promote regulation of cell cycle and apoptosis, and it is frequently upregulated in certain subgroups of HCCs. Moreover, several growth factors and their receptors are, interestingly, involved in HCC pathogenesis. In particular both EGFR and VEGFR are overexpressed in
tumor tissue and possibly play a role in neoplastic cell growth and metastatization.\textsuperscript{26}

**Targeted treatment therapies – safety and efficacy**

As mentioned above, sorafenib is recommended as the first-line option in patients who cannot benefit from resection, transplantation, ablation, or transarterial chemoembolization, and still have preserved liver function.\textsuperscript{10}

The multicenter SHARP trial randomly assigned 602 patients with inoperable HCC and Child–Pugh A cirrhosis to sorafenib (400 mg twice daily) or placebo.\textsuperscript{11} Overall survival, the primary end-point, was significantly longer in the sorafenib-treated patients (10.7 vs 7.9 months), as was time to radiologic progression (5.5 vs 2.8 months).

The magnitude of benefit was markedly less in the second trial\textsuperscript{12} than in the SHARP trial. In fact, the treated group in the Asian trial had a shorter survival duration than the control group in the SHARP trial (6.5 vs 7.9 months), despite the fact that both trials used the same entry criteria. Nevertheless, patients accrued to the Asian study were more ill at the start of therapy than those in the SHARP trial, with a generally worse performance status and more advanced stage of disease.

Sorafenib was generally well tolerated and the overall incidence of serious adverse events in the sorafenib and placebo groups was comparable (52\% and 54\%, respectively). Drug-related adverse events (diarrhea, hand–foot skin syndrome [HFSR], anorexia, weight loss, asthenia, alopecia, and voice changes), especially of grade 1 or 2 severity, were observed more frequently in the sorafenib group than in the placebo group (80\% vs 52\%). The two most common grade 3 adverse reactions with sorafenib were HFSR (8\%) and diarrhea (8\%). There were no significant differences in discontinuation rates between the sorafenib and the placebo group (38\% and 37\% respectively) because of adverse events. The safety profile of sorafenib was comparable to those of the subsequent Asia–Pacific Phase III trial that enrolled patients of Eastern countries with similar eligibility criteria.

However, reports of its tolerability and efficacy in a real-life setting (outside RCTs) are still scarce. A recent report, published as an abstract, showed that during treatment with sorafenib occurrence of adverse events of any grade is common (89\%) and often requires dose reduction or discontinuation. Moreover, in this study, the overall 1-year survival rate was not significantly different between patients who received full dose and patients who received reduced dose. Dose-ranging studies in order to assess the individual effective dose may be required.\textsuperscript{27}

Several new molecular targeted therapies are under clinical development for the treatment of advanced HCC including anti-EGFR molecules such as erlotinib, monoclonal antibodies against VEGF such as bevacizumab, and antiangiogenic agents such as sunitinib, brivanib, or linifanib (Table 2).

Bevacizumab is a recombinant humanized monoclonal antibody against VEGF-A. In a multicenter Phase II study, 46 patients with Child–Pugh A class cirrhosis and unresectable HCC with no extrahepatic disease and vascular involvement were enrolled; 6-month progression-free survival was achieved in 65\% of these patients, with a 13\% rate of partial response to treatment.\textsuperscript{28} Bevacizumab has also been evaluated in combination with chemotherapy in several Phase II studies. In a Phase II study, 33 patients, even with metastatic disease, treated with bevacizumab, gemcitabine, and oxaliplatin achieved a 20\% response rate with an overall median survival time of 9.6 months.\textsuperscript{29} A Phase II trial of bevacizumab and erlotinib showed a response rate of 25\% with a median overall survival of 68 weeks.\textsuperscript{30} On the basis of these results, bevacizumab, alone or in combination, may have an antitumoral activity against HCC, but its efficacy and tolerability profile, in particular because of the increased risk of variceal bleeding and thromboembolic events, requires further evaluation.

Brivanib alanate is an inhibitor of VEGFR and fibroblast growth factor receptor tyrosine kinases. At present a large randomized Phase III trial is studying brivanib as second-line therapy in HCC patients who have progressed on sorafenib.\textsuperscript{31}

Sunitinib is another oral multikinase inhibitor against VEGFR1, VEGFR2, platelet derived growth factor receptor (PDGFR) alfa and beta, c-Kit, FLT3, and RET kinases. After two Phase II trials\textsuperscript{32,33} which analyzed efficacy and tolerability of sunitinib in advanced HCC, a Phase III trial comparing sunitinib and sorafenib was conducted. Unfortunately it has been recently discontinued because of the high incidence of serious adverse effects in the sunitinib arm of study.\textsuperscript{31}

Erlotinib is an oral EGFR inhibitor against its tyrosine kinase domain. Two Phase II studies investigated efficacy of erlotinib in advanced HCC\textsuperscript{34,35} and a Phase III trial in combination with sorafenib is ongoing.\textsuperscript{31} A combination of erlotinib and bevacizumab versus sorafenib is now being studied in a multicenter Phase II trial.\textsuperscript{31}

Linifanib (ABT-869) is an oral agent that acts as a selective inhibitor of VEGF and PDGF tyrosine kinase receptors that...
## Table 2: Systemic therapy trials in advanced hepatocellular carcinoma (HCC)

<table>
<thead>
<tr>
<th>Regimen/trial name</th>
<th>Study author</th>
<th>Phase</th>
<th>No. of patients</th>
<th>Results/preliminary data*</th>
<th>Drug name/mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II trial evaluating clinical and biological effects of bevacizumab in unresectable hepatocellular carcinoma</td>
<td>Siegel et al28</td>
<td>II</td>
<td>46</td>
<td>OS 12.4 months, PSF 6.9 months</td>
<td>Bevacizumab: mAb against VEGF</td>
</tr>
<tr>
<td>Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma</td>
<td>Zhu et al29</td>
<td>II</td>
<td>17</td>
<td>OS 9.6 months, PFS 5.3 months</td>
<td>Bevacizumab: mAb against VEGF; oxaliplatin: alkylating agent, inhibition of DNA synthesis; gemcitabine: nucleoside analog, arrest of DNA replication</td>
</tr>
<tr>
<td>Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma</td>
<td>Thomas et al30</td>
<td>II</td>
<td>40</td>
<td>OS 68 weeks, PFS 39 weeks</td>
<td>Bevacizumab: mAb against VEGF; erlotinib: RTK inhibits EGFR1</td>
</tr>
<tr>
<td>Comparison of brivanib and best supportive care to placebo for treatment of liver cancer for those subjects who have failed sorafenib treatment</td>
<td></td>
<td>III</td>
<td>340</td>
<td>Recruiting participants31</td>
<td>Brivanib: inhibition of FGF1 and VEGFR2</td>
</tr>
<tr>
<td>Study of sunitinib malate versus sorafenib in patients with inoperable liver cancer</td>
<td></td>
<td>III</td>
<td>1200</td>
<td>Discontinued on April 2010 because of high rate of severe adverse effect on sunitinib arm31</td>
<td>Sunitinib: inhibition of VEGF-R2 and PDGF-R beta tyrosine kinase</td>
</tr>
<tr>
<td>Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)</td>
<td></td>
<td>III</td>
<td></td>
<td>Recruiting participants31</td>
<td>Erlotinib: RTK inhibits EGFR1; sorafenib: multikinase inhibitor of Raf, VEGFR2, PDGFR, FLT3, MEK and ERK</td>
</tr>
<tr>
<td>Bevacizumab and erlotinib or sorafenib as first-line therapy in treating patients with advanced liver cancer</td>
<td>Thomas et al30</td>
<td>II</td>
<td>120</td>
<td>Recruiting participants31</td>
<td>Bevacizumab: mAb against VEGF; erlotinib: RTK inhibits EGFR1; sorafenib: multikinase inhibitor of Raf, VEGFR2, PDGFR, FLT3, MEK and ERK</td>
</tr>
<tr>
<td>Phase II study of ABT-869 in hepatocellular carcinoma (HCC)</td>
<td>Tog et al36</td>
<td>II</td>
<td>44</td>
<td>Active, not recruiting81</td>
<td>ABT-869: selective inhibitor of VEGF and PDGF tyrosine kinase receptors</td>
</tr>
<tr>
<td>Efficacy and tolerability of ABT-869 versus sorafenib in advanced hepatocellular carcinoma</td>
<td></td>
<td>III</td>
<td></td>
<td>Recruiting participants31</td>
<td>ABT-869: selective inhibitor of VEGF and PDGF tyrosine kinase receptors; sorafenib: multikinase inhibitor of Raf, VEGFR2, PDGFR, FLT3, MEK and ERK</td>
</tr>
</tbody>
</table>

**Abbreviations:** VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2; PDGFR, platelet-derived growth factor receptor; FLT3, FMS-like tyrosine kinase 3; MEK, mitogen-activated protein (MAP/extracellular signal related kinase ERK) kinase; EGFR1, endothelial growth factor receptor 1; RTK, receptor tyrosine kinase; mAb, monoclonal antibody; OS, overall survival; PFS, progression-free survival.

was recently evaluated in a Phase II trial conducted on Child–Pugh A or B cirrhotic patients that reported a median time to progression and progression-free survival of 112 days with a median overall survival of 295 days. Preliminary pharmacokinetics analysis in Child Pugh A and B patients showed that degree of hepatic impairment of tumor extent do not influence linifanib pharmacokinetics. Its safety profile was acceptable and therefore a new Phase III study
comparing linifanib with sorafenib in patients with advanced HCC is ongoing.31

Implications for future work and enhanced patient care

Despite the use of aggressive treatments such as resection, OLT, PEI, RFA, and TACE, tumor recurrence and the development of extrahepatic metastases continue to have a marked effect on survival of patients with HCC.

Several steps are required to improve the effectiveness of HCC therapy, including the implementation of screening programs to increase the number of patients diagnosed in early stages of disease, and improving patients' access to specialized, multidisciplinary treatments (ie, pharmacological, interventional, radiological, and surgical).

Image-guided loco-regional therapies have long been used in the setting of combined treatment strategies to improve their efficacy and effectiveness.

An accepted indication is the use of interventional treatment in patients awaiting transplantation to prevent tumor progression when the waiting time exceeds 6 months.38

A combination of TACE followed by RFA or PEI has been used to minimize heat loss due to perfusion-mediated tissue cooling and thus increase the therapeutic effect of RFA.13,14

Combination treatment with RFA plus PEI can improve survival compared with the use of RFA alone in selected patients.39 However, large RCTs should be performed to confirm the efficacy of these combination therapies.

The impact of sorafenib on advanced-stage HCC is a landmark finding in the treatment of liver cancer. Moreover, the potential value of antiangiogenic and antiproliferative properties of sorafenib is currently under evaluation for early and intermediate stages in preventing recurrence. In fact, two studies31 that aim to evaluate the effect of sorafenib versus placebo after curative treatment (adjuvant therapy), and the effect of sorafenib versus placebo in combination with TACE (combined therapy), have already been initiated.

The Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) RCT is an international study that is evaluating effects of sorafenib versus placebo after resection or local ablation. The primary end-point of this RCT is recurrence-free survival. The Sorafenib or Placebo in Combination with TACE in hepatocellular carcinoma (SPACE) is investigating the

Figure 5 A) Treatment allocation according to American Association of Liver Diseases guidelines;10 B) Proposed extended use of sorafenib outside RCTs for intermediate and advanced stage after disease progression (growth lesions and new lesions).40–42

Abbreviation: TACE, transarterial chemoembolization.
combination of sorafenib and TACE in patients with intermediate HCC with the aim of reducing risk of local relapse after this procedure.

Recently, although in the absence of solid evidence, panels of experts proposed shifting therapy to sorafenib in patients in intermediate stage if they showed poor tolerance or disease progression (new lesions or growth lesions) after first or second TACE.\(^{40,41}\) and suggested continuing treatment with sorafenib even if patients previously treated with sorafenib showed disease progression during treatment\(^{42}\) (Figure 5). However, well-conducted large studies are needed to evaluate these treatment approaches.

Several targeted agents are under investigation, which show encouraging results in Phase II studies. Their efficacy and safety has yet to be proven in Phase III RCTs. The combination of multiple, targeted agents may be the next logical step in the treatment of HCC due to the strong rationale of inhibiting signaling pathways in hepatocarcinogenesis.

### Conclusions and discussion

Undoubtedly, the best way to prevent the development of HCC is the prevention of risk factors leading to chronic injury (primary prevention). Vaccination against hepatitis B (HBV) has decreased the incidence of HBV-related HCC. Vaccination against hepatitis C (HCV) is not yet possible, and prevention of HCV infection relies on the implementation of adequate public health measures.

A major challenge remains the early diagnosis of HCC in order to allow a potentially curative treatment approach (secondary prevention). HCC surveillance by abdominal ultrasound should be performed on all patients at risk at 6-month intervals.

Diagnosis of HCC at an early stage provides the opportunity for therapy (resection, OLT, percutaneous ablation) with the aim of complete response and potential long-term cure.

TACE is the recommended treatment modality for HCC at intermediate stage with well-preserved liver function.

Sorafenib is the standard treatment for intermediate or advanced stage HCC beyond the benefit of liver transplantation, surgery, and loco-regional therapies. It is suggested as the control in first-line trials for advanced HCC. Trials comparing new agents with sorafenib and new agents in combination with sorafenib against sorafenib alone are a priority. In the absence of standard-of-care second-line therapy, randomized second-line trials should be placebo controlled.

Despite the availability of several treatment options, tumor recurrence and metastatic disease continue to have an important role on survival, and for this reason there is urgent need for effective neoadjuvant and adjuvant therapies in order to enhance benefits of these approaches. The advent of systemic therapies for HCC and in particular the success of antiangiogenic molecules such as sorafenib has opened a new window on promising clinical research that may potentially affect the future treatment of this disease. Sorafenib has been shown to effectively prolong survival in patients with advanced HCC and preserved liver function but many other molecularly targeted agents, used alone or in combination, are in different stages of clinical development. Combination of systemic therapies with local treatments in patients with HCC is still being evaluated but holds the promise of further improvements in patient outcomes. Well-conducted, randomized controlled trials to examine the effectiveness of different multimodal approaches are urgently needed.

Given the complexity of the disease (in particular for the presence of chronic liver disease) and the large number of potentially useful therapies, it is not surprising that the expertise of many physicians is required to provide optimal care to patients with HCC. Patients diagnosed with liver cancer should be referred to multidisciplinary teams including hepatologists, gastroenterologists, surgical oncologists, transplant surgeons, medical oncologists, radiation oncologists, diagnostic radiologists, interventional radiologists, primary care physicians, palliative care physicians, and allied health professionals, all of whom should play an active role in the care of these patients. Treatment decisions should be discussed in multidisciplinary meetings, as no single treatment strategy can be applied to all patients, and treatment must be individualized.

### Disclosure

The authors disclose no conflicts of interest.

### References